Dumont Blake Investment Advisors Lowers stake in Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific (TMO) : Dumont Blake Investment Advisors reduced its stake in Thermo Fisher Scientific by 1.81% during the most recent quarter end. The investment management company now holds a total of 5,796 shares of Thermo Fisher Scientific which is valued at $851,143 after selling 107 shares in Thermo Fisher Scientific , the firm said in a disclosure report filed with the SEC on Apr 21, 2016.Thermo Fisher Scientific makes up approximately 0.44% of Dumont Blake Investment Advisors’s portfolio.

Thermo Fisher Scientific opened for trading at $145.61 and hit $147.7521 on the upside on Wednesday, eventually ending the session at $147.14, with a gain of 1.05% or 1.53 points. The heightened volatility saw the trading volume jump to 14,97,750 shares. Company has a market cap of $58,306 M.

Other Hedge Funds, Including , Transamerica Financial Advisors reduced its stake in TMO by selling 7,778 shares or 77.06% in the most recent quarter. The Hedge Fund company now holds 2,316 shares of TMO which is valued at $340,105. Thermo Fisher Scientific makes up approx 0.03% of Transamerica Financial Advisors’s portfolio.Raymond James Trust N.a. reduced its stake in TMO by selling 640 shares or 8.56% in the most recent quarter. The Hedge Fund company now holds 6,833 shares of TMO which is valued at $1,003,426. Thermo Fisher Scientific makes up approx 0.09% of Raymond James Trust N.a.’s portfolio.Btim Corp. reduced its stake in TMO by selling 225 shares or 8.21% in the most recent quarter. The Hedge Fund company now holds 2,517 shares of TMO which is valued at $369,621. Thermo Fisher Scientific makes up approx 0.01% of Btim Corp.’s portfolio.National Investment Services Inc Wi reduced its stake in TMO by selling 264 shares or 1.37% in the most recent quarter. The Hedge Fund company now holds 19,066 shares of TMO which is valued at $2,799,842. Thermo Fisher Scientific makes up approx 3.13% of National Investment Services Inc Wi’s portfolio.

On the company’s financial health, Thermo Fisher Scientific reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Jan 28, 2016. Analyst had a consensus of $2.11. The company had revenue of $4652.50 million for the quarter, compared to analysts expectations of $4551.79 million. The company’s revenue was up 3.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.99 EPS.

Many Wall Street Analysts have commented on Thermo Fisher Scientific. Company shares were Reiterated by Mizuho on Apr 4, 2016 to “Buy”, Firm has raised the Price Target to $ 160 from a previous price target of $150 .Company shares were Reiterated by Topeka Capital Markets on Mar 2, 2016 to “Buy”, Firm has raised the Price Target to $ 155 from a previous price target of $145 .

Thermo Fisher Scientific Inc. is a provider of analytical instruments equipment reagents and consumables software and services for research manufacturing analysis discovery and diagnostics. The company operates through four segments: Life Sciences Solutions provides reagents instruments and consumables used in biological and medical research discovery and production of new drugs and vaccines as well as diagnosis of disease; Analytical Instruments provides instruments consumables software and services that are used in the laboratory; Specialty Diagnostics offers diagnostic test kits reagents culture media instruments and associated products and Laboratory Products and Services offers self-manufactured and sourced products for the laboratory.

Leave a Reply

Thermo Fisher Scientific - Is it time to Sell?

Top Brokerage Firms are advising their investors on Thermo Fisher Scientific. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.